Administrative Core

行政核心-摘要 拟议的免疫转运肿瘤物理学中心（CITO）的重点是识别和 了解免疫细胞和分子的多尺度传输特性，无论是系统性的， 以及肿瘤的其他特定生物学和物理特性 微环境，以最终开发有效的癌症免疫疗法。CITO主要组件 总结如下。项目1提出确定树突状细胞（DC）的转运现象 乳腺癌和胰腺癌的疫苗以及疫苗接种后内源性DC转运的变化， 效应T细胞和大分子药物。这些信息将用于改善免疫反应， 这两个癌症模型。项目2旨在确定多尺度传输现象的影响， 胰腺导管腺癌（PDAC）对肿瘤内免疫细胞和营养物质分布的影响 微环境，在肿瘤的发展过程中。运输实体物理学核心（TOC）将支持 具有建模、计算和成像能力的项目，将科学数据集成为参数 这最终为最佳癌症免疫治疗的合理设计提供了信息， 乳腺癌和胰腺癌的免疫原性，这两种癌症在历史上都是低免疫原性的。 免疫原性。教育和外展股将作为交流和接触股， 为学生，学员，初级教师调查员和CITO的研究人员以及 物理科学-肿瘤学网络（PS-ON）及其他。将建立行政核心（AC） 作为CITO基础设施的一部分，首席研究员（PI），项目共同领导人和核心 领导者，研究人员，学员，顾问，NCI PS-ON计划工作人员，以及其他科学和患者 社区可以分享信息，协同开展与CITO有关的活动。AC将促进 实现和评估进展，并建立一个合作网络， 物理科学和肿瘤学的科学家。顾问委员会亦会监督及管理 试点和跨网络项目，协调共享资源和设施的使用，并促进 与其他PS-ON研究者的互动。Mauro Ferrari博士（中心PI，高级物理科学研究员， AC共同负责人，TOC负责人;休斯顿卫理公会研究所，HMRI）将担任AC共同负责人 (10%努力）。Elizabeth Mittendorf博士（中心癌症临床翻译研究员; AC共同负责人;项目1 共同负责人; MD安德森癌症中心），王荣福博士（中心高级癌症免疫学研究者; AC共同负责人;项目1共同负责人; HMRI）和Rolf Brekken博士（高级癌症生物学研究员; AC共同负责人; 领导人;项目2共同领导人; UT西南医学中心）也将担任其他三个AC共同， 领导者（AC中每个人的工作量为5%）。他们将得到中心管理员和工作人员的支持。

ADMINISTRATIVE CORE – SUMMARY The proposed Center for Immunotherapeutic Transport Oncophysics (CITO) is focused on identifying and understanding the multi-scale transport properties of immune cells and molecules, both systemically and within the tumor microenvironment, and other specific biological and physical properties of the tumor microenvironment, to ultimately develop effective cancer immunotherapies. The major CITO components are summarized as follows. Project 1 proposes to determine the transport phenomena of dendritic cell (DC) vaccines for breast and pancreatic cancers and post-vaccination changes in the transport of endogenous DCs, effector T cells, and macromolecular drugs. This information will be used to improve immune responses in these two cancer models. Project 2 seeks to determine the effects of multi-scale transport phenomena of pancreatic ductal adenocarcinoma (PDAC) on the distribution of immune cells and nutrients in the tumor microenvironment, during tumor progression. The Transport Oncophysics Core (TOC) will support both projects with modeling, computational, and imaging capabilities to integrate the scientific data into parameters that ultimately inform the rational design of optimal cancer immunotherapeutics and to improve the immunogenicity of breast and pancreatic cancers, both of which are historically known to be lowly immunogenic. The Education and Outreach Unit (EOU) will serve as the communication and engagement platform for students, trainees, junior faculty investigators, and researchers of the CITO, and those of the Physical Sciences-Oncology Network (PS-ON) and beyond. The Administrative Core (AC) will be established as part of the CITO infrastructure through which the Principal Investigator (PI), Project Co-Leaders and Core Leader, researchers, trainees, advisors, NCI PS-ON program staff, and other scientific and patient communities can share information and synergize CITO-related activities. The AC will facilitate the accomplishment and evaluation of progress and the creation of a collaborative network for current and future scientists in physical sciences oncology. The AC will also oversee and manage the selection and funding of Pilot and Trans-Network Projects, coordinate the use of shared resources and facilities, and promote interaction with other PS-ON investigators. Dr. Mauro Ferrari (Center PI, senior physical sciences investigator, AC Co-Leader, TOC Leader; Houston Methodist Research Institute, HMRI) will serve as the AC Co-Leader (10% effort). Dr. Elizabeth Mittendorf (Center cancer clinical translation investigator; AC Co-Leader; Project 1 Co-Leader; MD Anderson Cancer Center), Dr. Rongfu Wang (Center senior cancer immunology investigator; AC Co-Leader; Project 1 Co-Leader; HMRI), and Dr. Rolf Brekken (senior cancer biology investigator; AC Co- Leader; Project 2 Co-Leader; UT Southwestern Medical Center) will also serve as the other three AC Co- Leaders (5% effort each in the AC). They will be supported by a Center Administrator and staff.